Advances in FDA’s Safety Program for Marketed Drugs
The Food and Drug Administration has issued a new report stating that its postmarket drug safety program has been strengthened and modernized and has resulted in a substantial improvement in the FDA’s oversight of drugs once they reach the American public. The report, “Advances in FDA’s Safety Program for Marketed Drugs,” describes new scientific tools and enhanced capabilities that give the same priority to postmarket drug safety monitoring as to premarket drug review. It was issued by the FDA Center for Drug Evaluation and Research (CDER): http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm301165.htm?source=govdelivery.
